April 22, 2025 • 10 mins
In Episode 135 of the U.S. News Daily Brief, Michelle kicks off with a welcome and introduction before diving into Roche's significant $50 billion investment in the U.S. and Walgreens' opioid settlement, discussing their implications for healthcare and the economy. The episode then examines a Supreme Court case concerning the Affordable Care Act's preventive-care provisions, highlighting potential changes to healthcare access. Michelle provides a market update, focusing on the Dow Jones drop and its effects on the tech sector amid global trade tensions and market uncertainty. The episode wraps up with a call for listeners to stay informed on these vital issues.
Mark as Played
Transcript
Episode Transcript
Available transcripts are automatically generated. Complete accuracy is not guaranteed.
(00:00):
Welcome back to U.S.
(00:01):
News Daily, your go-to update on the latesthappenings across the United States.
I’m your host, AI Michelle, and this is aMagicPod, produced by PodcastAI.
Want to create your own MagicPod?
Click the link in the show notes.
Alright, let’s dive in.
First up...
In a significant move, Roche, the Swisspharmaceutical giant, has announced a massive
(00:28):
investment of fifty billion dollars in theUnited States over the next five years.
This investment is aimed at bolstering itspresence in the American market and
accelerating its research and developmentcapabilities.
The company plans to channel these funds intoexpanding its manufacturing facilities,
enhancing its research infrastructure, andfostering innovation in drug development.
(00:51):
Roche's decision underscores the importance ofthe United States as a critical market for
global pharmaceutical companies.
With this investment, Roche aims to createthousands of jobs, boost local economies, and
contribute to the advancement of healthcaresolutions in the country.
This move is expected to not only strengthenRoche's competitive edge but also enhance the
(01:14):
United States' standing as a hub forpharmaceutical innovation.
This development comes at a time when thepharmaceutical industry is under pressure to
innovate rapidly in response to global healthchallenges.
Roche's commitment to invest heavily in theUnited States reflects its confidence in the
country's potential to lead in medicaladvancements and its strategic importance in
(01:35):
the global healthcare landscape.
Walgreens has reached a significant settlementwith the United States government, agreeing to
pay up to three hundred and fifty milliondollars.
This settlement resolves allegations that thepharmacy chain illegally filled millions of
unlawful opioid prescriptions and submittedfalse claims to federal health care programs.
(01:55):
The Justice Department, along with the DrugEnforcement Administration and the Department
of Health and Human Services Office ofInspector General, announced the settlement,
which involves Walgreens Boots Alliance,Walgreen Company, and various subsidiaries.
The settlement includes three hundred milliondollars to address the claims under the False
Claims Act related to the illegal filling ofopioid prescriptions.
(02:18):
An additional fifty million dollars will berequired if Walgreens undergoes a sale, merger,
or transfer before fiscal year twentythirty-two.
The allegations span from August two thousandtwelve through March first, two thousand
twenty-three.
During this period, Walgreens is accused ofknowingly filling prescriptions that were not
(02:40):
legitimate, including excessive quantities ofopioids and prescriptions filled significantly
earlier than permitted.
As part of the settlement, Walgreens willimplement a compliance program to prevent such
violations in the future.
This program includes policies and proceduresto ensure pharmacists verify the validity of
prescriptions, annual training for pharmacyemployees, and measures to block prescriptions
(03:04):
from prescribers identified as problematic.
Walgreens will also maintain sufficientstaffing and a system for monitoring
prescribers to ensure compliance with theControlled Substances Act.
This settlement represents one of the largestresolutions of its kind under the Controlled
Substances Act, highlighting the government’scommitment to combating the opioid crisis.
(03:27):
The Justice Department emphasized thatpharmacies have a legal and professional
responsibility to dispense controlledsubstances safely and not prioritize profit
over patient safety.
The settlement aims to ensure that Walgreensadheres to these responsibilities moving
forward, protecting both patients and taxpayerfunds from fraudulent claims.
(03:49):
The Supreme Court is currently reviewing asignificant case that could affect whether
Americans will continue to receivepreventive-care services at no cost under the
Affordable Care Act.
These services include essential screenings fordiabetes, HIV-prevention drugs, and statins.
This legal battle focuses on the classificationof the sixteen members of the United States
(04:11):
Preventive Services Task Force, a group withinthe Department of Health and Human Services
that has been advising on preventive medicalservices since 1984.
Last year, a federal appeals court in NewOrleans ruled that the task force's structure
violates the Constitution's AppointmentsClause.
The court found that the task force members areprincipal officers who must be appointed by the
(04:35):
president and confirmed by the Senate,something that has not been done.
If the Supreme Court upholds this decision, itcould restrict access to vital medical care for
millions, as insurers may no longer be requiredto cover these services without cost to
patients.
Major hospital associations and nonprofits havewarned that patients might forgo essential
(04:58):
preventive care if they have to bear the coststhemselves.
The task force's role was formally establishedby Congress in 1999, and with the passage of
the Affordable Care Act, health insurers wererequired to cover certain preventive services
without imposing additional costs on patients.
However, Congress did not specify whichservices, relying instead on expert
(05:22):
recommendations from the task force.
During the Supreme Court arguments, JusticeBrett Kavanaugh noted differences in the
statutory language that established the taskforce compared to other independent agencies.
He questioned whether the task force'srecommendations are indeed as influential as
argued.
Justice Elena Kagan highlighted the importanceof the secretary's ability to remove task force
(05:47):
members as a sign of accountability, suggestingthat this might challenge the characterization
of them as principal officers.
If the Supreme Court finds the task forcemembers are inferior officers, the case may
return to the Fifth Circuit to determine ifCongress intended for the Health and Human
Services secretary to appoint them.
(06:07):
The case arose after the task force recommendedthat HIV-prevention drugs, known as PrEP, be
covered without cost-sharing, which someplaintiffs opposed on religious grounds.
These plaintiffs argue that the task force'sstructure is unconstitutional and that their
recommendations should not mandate insurancecoverage.
(06:28):
Legal experts and medical organizations haveexpressed concern that invalidating the task
force's structure would have severeconsequences for public health, potentially
reversing decades of progress in diseaseprevention.
The Supreme Court's decision, expected by theend of June or early July, will be pivotal in
determining the future of preventive healthcareaccess under the Affordable Care Act.
(06:52):
In a dramatic turn of events, the Dow JonesIndustrial Average took a nosedive, dropping
971.82 points to close at 38,170.41.
This significant slide of 2.48% came as formerPresident Donald Trump ramped up his criticism
of Federal Reserve Chair Jerome Powell,reigniting investor concerns about the central
(07:14):
bank's independence.
The S&P 500 and Nasdaq Composite also tookhits, sliding 2.36% and 2.55% respectively.
Trump's comments on social media, where helabeled Powell as "Mr.
Too Late, a major loser," and called forimmediate interest rate cuts, added fuel to the
(07:34):
fire.
This follows his earlier hints at possiblyterminating Powell, a move that White House
economic advisor Kevin Hassett suggested wasunder review.
The uncertainty surrounding the FederalReserve's future actions has left investors
jittery, contributing to the market'svolatility.
The tech sector, often dubbed the "MagnificentSeven," was particularly hard hit.
(07:59):
Tesla and Nvidia saw declines of 5.8% and over4%, respectively.
Amazon and Meta Platforms each shed 3%.
The turmoil in the markets also affectedequipment manufacturer Caterpillar, which fell
by 2.8%.
Meanwhile, the dollar weakened, reaching athree-year low as Trump's threats intensified.
(08:23):
In contrast, gold prices hit record highs,soaring above $3,400 per ounce, as investors
sought safe havens amid the market turbulence.
The ongoing lack of progress on global tradetalks further added to investor anxiety.
Tensions with China escalated, with Beijingwarning other nations against making deals with
(08:45):
the United States that could undermine itsinterests.
This uncertainty has weighed heavily oninvestor confidence, with the S&P 500 down 9%
since the beginning of April, following Trump'sannouncement of new tariffs.
Analysts like Michael Green of Simplify AssetManagement and Robert Haworth of U.S.
(09:07):
Bank highlighted the challenge of navigatingthis environment, noting that the market is
struggling to find direction amid theuncertainty surrounding tariffs and interest
rates.
They warned that prolonged uncertainty couldfurther impact corporate earnings and strategic
decision-making.
Despite the downturn, some analysts remainoptimistic about the market's resilience.
(09:30):
John Stoltzfus of Oppenheimer noted that thefundamentals still show signs of a strong bull
market, driven by consumer spending, earningsgrowth, and job growth.
However, he acknowledged the currentenvironment of uncertainty and volatility.
As we look ahead, the market's focus willlikely remain on the Federal Reserve's next
moves and the progress of trade negotiations.
(09:52):
Investors will be closely watching anydevelopments that could provide clarity and
stability in these tumultuous times.
Alright, that's a wrap for this episode.
If you enjoyed this brief, and would like tostay updated on latest episodes, don’t forget
to click ‘Follow’ in your podcast app.
Thanks again for listening, and hope to catchyou next time.
Welcome back to U.S.
(00:01):
News Daily, your go-to update on the latesthappenings across the United States.
I’m your host, AI Michelle, and this is aMagicPod, produced by PodcastAI.
Want to create your own MagicPod?
Click the link in the show notes.
Alright, let’s dive in.
First up...
In a significant move, Roche, the Swisspharmaceutical giant, has announced a massive
(00:28):
investment of fifty billion dollars in theUnited States over the next five years.
This investment is aimed at bolstering itspresence in the American market and
accelerating its research and developmentcapabilities.
The company plans to channel these funds intoexpanding its manufacturing facilities,
enhancing its research infrastructure, andfostering innovation in drug development.
(00:51):
Roche's decision underscores the importance ofthe United States as a critical market for
global pharmaceutical companies.
With this investment, Roche aims to createthousands of jobs, boost local economies, and
contribute to the advancement of healthcaresolutions in the country.
This move is expected to not only strengthenRoche's competitive edge but also enhance the
(01:14):
United States' standing as a hub forpharmaceutical innovation.
This development comes at a time when thepharmaceutical industry is under pressure to
innovate rapidly in response to global healthchallenges.
Roche's commitment to invest heavily in theUnited States reflects its confidence in the
country's potential to lead in medicaladvancements and its strategic importance in
(01:35):
the global healthcare landscape.
Walgreens has reached a significant settlementwith the United States government, agreeing to
pay up to three hundred and fifty milliondollars.
This settlement resolves allegations that thepharmacy chain illegally filled millions of
unlawful opioid prescriptions and submittedfalse claims to federal health care programs.
(01:55):
The Justice Department, along with the DrugEnforcement Administration and the Department
of Health and Human Services Office ofInspector General, announced the settlement,
which involves Walgreens Boots Alliance,Walgreen Company, and various subsidiaries.
The settlement includes three hundred milliondollars to address the claims under the False
Claims Act related to the illegal filling ofopioid prescriptions.
(02:18):
An additional fifty million dollars will berequired if Walgreens undergoes a sale, merger,
or transfer before fiscal year twentythirty-two.
The allegations span from August two thousandtwelve through March first, two thousand
twenty-three.
During this period, Walgreens is accused ofknowingly filling prescriptions that were not
(02:40):
legitimate, including excessive quantities ofopioids and prescriptions filled significantly
earlier than permitted.
As part of the settlement, Walgreens willimplement a compliance program to prevent such
violations in the future.
This program includes policies and proceduresto ensure pharmacists verify the validity of
prescriptions, annual training for pharmacyemployees, and measures to block prescriptions
(03:04):
from prescribers identified as problematic.
Walgreens will also maintain sufficientstaffing and a system for monitoring
prescribers to ensure compliance with theControlled Substances Act.
This settlement represents one of the largestresolutions of its kind under the Controlled
Substances Act, highlighting the government’scommitment to combating the opioid crisis.
(03:27):
The Justice Department emphasized thatpharmacies have a legal and professional
responsibility to dispense controlledsubstances safely and not prioritize profit
over patient safety.
The settlement aims to ensure that Walgreensadheres to these responsibilities moving
forward, protecting both patients and taxpayerfunds from fraudulent claims.
(03:49):
The Supreme Court is currently reviewing asignificant case that could affect whether
Americans will continue to receivepreventive-care services at no cost under the
Affordable Care Act.
These services include essential screenings fordiabetes, HIV-prevention drugs, and statins.
This legal battle focuses on the classificationof the sixteen members of the United States
(04:11):
Preventive Services Task Force, a group withinthe Department of Health and Human Services
that has been advising on preventive medicalservices since 1984.
Last year, a federal appeals court in NewOrleans ruled that the task force's structure
violates the Constitution's AppointmentsClause.
The court found that the task force members areprincipal officers who must be appointed by the
(04:35):
president and confirmed by the Senate,something that has not been done.
If the Supreme Court upholds this decision, itcould restrict access to vital medical care for
millions, as insurers may no longer be requiredto cover these services without cost to
patients.
Major hospital associations and nonprofits havewarned that patients might forgo essential
(04:58):
preventive care if they have to bear the coststhemselves.
The task force's role was formally establishedby Congress in 1999, and with the passage of
the Affordable Care Act, health insurers wererequired to cover certain preventive services
without imposing additional costs on patients.
However, Congress did not specify whichservices, relying instead on expert
(05:22):
recommendations from the task force.
During the Supreme Court arguments, JusticeBrett Kavanaugh noted differences in the
statutory language that established the taskforce compared to other independent agencies.
He questioned whether the task force'srecommendations are indeed as influential as
argued.
Justice Elena Kagan highlighted the importanceof the secretary's ability to remove task force
(05:47):
members as a sign of accountability, suggestingthat this might challenge the characterization
of them as principal officers.
If the Supreme Court finds the task forcemembers are inferior officers, the case may
return to the Fifth Circuit to determine ifCongress intended for the Health and Human
Services secretary to appoint them.
(06:07):
The case arose after the task force recommendedthat HIV-prevention drugs, known as PrEP, be
covered without cost-sharing, which someplaintiffs opposed on religious grounds.
These plaintiffs argue that the task force'sstructure is unconstitutional and that their
recommendations should not mandate insurancecoverage.
(06:28):
Legal experts and medical organizations haveexpressed concern that invalidating the task
force's structure would have severeconsequences for public health, potentially
reversing decades of progress in diseaseprevention.
The Supreme Court's decision, expected by theend of June or early July, will be pivotal in
determining the future of preventive healthcareaccess under the Affordable Care Act.
(06:52):
In a dramatic turn of events, the Dow JonesIndustrial Average took a nosedive, dropping
971.82 points to close at 38,170.41.
This significant slide of 2.48% came as formerPresident Donald Trump ramped up his criticism
of Federal Reserve Chair Jerome Powell,reigniting investor concerns about the central
(07:14):
bank's independence.
The S&P 500 and Nasdaq Composite also tookhits, sliding 2.36% and 2.55% respectively.
Trump's comments on social media, where helabeled Powell as "Mr.
Too Late, a major loser," and called forimmediate interest rate cuts, added fuel to the
(07:34):
fire.
This follows his earlier hints at possiblyterminating Powell, a move that White House
economic advisor Kevin Hassett suggested wasunder review.
The uncertainty surrounding the FederalReserve's future actions has left investors
jittery, contributing to the market'svolatility.
The tech sector, often dubbed the "MagnificentSeven," was particularly hard hit.
(07:59):
Tesla and Nvidia saw declines of 5.8% and over4%, respectively.
Amazon and Meta Platforms each shed 3%.
The turmoil in the markets also affectedequipment manufacturer Caterpillar, which fell
by 2.8%.
Meanwhile, the dollar weakened, reaching athree-year low as Trump's threats intensified.
(08:23):
In contrast, gold prices hit record highs,soaring above $3,400 per ounce, as investors
sought safe havens amid the market turbulence.
The ongoing lack of progress on global tradetalks further added to investor anxiety.
Tensions with China escalated, with Beijingwarning other nations against making deals with
(08:45):
the United States that could undermine itsinterests.
This uncertainty has weighed heavily oninvestor confidence, with the S&P 500 down 9%
since the beginning of April, following Trump'sannouncement of new tariffs.
Analysts like Michael Green of Simplify AssetManagement and Robert Haworth of U.S.
(09:07):
Bank highlighted the challenge of navigatingthis environment, noting that the market is
struggling to find direction amid theuncertainty surrounding tariffs and interest
rates.
They warned that prolonged uncertainty couldfurther impact corporate earnings and strategic
decision-making.
Despite the downturn, some analysts remainoptimistic about the market's resilience.
(09:30):
John Stoltzfus of Oppenheimer noted that thefundamentals still show signs of a strong bull
market, driven by consumer spending, earningsgrowth, and job growth.
However, he acknowledged the currentenvironment of uncertainty and volatility.
As we look ahead, the market's focus willlikely remain on the Federal Reserve's next
moves and the progress of trade negotiations.
(09:52):
Investors will be closely watching anydevelopments that could provide clarity and
stability in these tumultuous times.
Alright, that's a wrap for this episode.
If you enjoyed this brief, and would like tostay updated on latest episodes, don’t forget
to click ‘Follow’ in your podcast app.
Thanks again for listening, and hope to catchyou next time.
Popular Podcasts
Stuff You Should Know
If you've ever wanted to know about champagne, satanism, the Stonewall Uprising, chaos theory, LSD, El Nino, true crime and Rosa Parks, then look no further. Josh and Chuck have you covered.
My Favorite Murder with Karen Kilgariff and Georgia Hardstark
My Favorite Murder is a true crime comedy podcast hosted by Karen Kilgariff and Georgia Hardstark. Each week, Karen and Georgia share compelling true crimes and hometown stories from friends and listeners. Since MFM launched in January of 2016, Karen and Georgia have shared their lifelong interest in true crime and have covered stories of infamous serial killers like the Night Stalker, mysterious cold cases, captivating cults, incredible survivor stories and important events from history like the Tulsa race massacre of 1921. My Favorite Murder is part of the Exactly Right podcast network that provides a platform for bold, creative voices to bring to life provocative, entertaining and relatable stories for audiences everywhere. The Exactly Right roster of podcasts covers a variety of topics including historic true crime, comedic interviews and news, science, pop culture and more. Podcasts on the network include Buried Bones with Kate Winkler Dawson and Paul Holes, That's Messed Up: An SVU Podcast, This Podcast Will Kill You, Bananas and more.
The Joe Rogan Experience
The official podcast of comedian Joe Rogan.